Cargando…

Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial

INTRODUCTION: Infusing arginine vasopressin (AVP) in vasodilatory shock usually decreases cardiac output and thus systemic oxygen transport. It is still a matter of debate whether this vasoconstriction impedes visceral organ blood flow and thereby causes organ dysfunction and injury. Therefore, we t...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Florian, Giudici, Ricardo, Scheuerle, Angelika, Gröger, Michael, Asfar, Pierre, Vogt, Josef A, Wachter, Ulrich, Ploner, Franz, Georgieff, Michael, Möller, Peter, Laporte, Régent, Radermacher, Peter, Calzia, Enrico, Hauser, Balázs
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750159/
https://www.ncbi.nlm.nih.gov/pubmed/19591694
http://dx.doi.org/10.1186/cc7959
_version_ 1782172216552587264
author Simon, Florian
Giudici, Ricardo
Scheuerle, Angelika
Gröger, Michael
Asfar, Pierre
Vogt, Josef A
Wachter, Ulrich
Ploner, Franz
Georgieff, Michael
Möller, Peter
Laporte, Régent
Radermacher, Peter
Calzia, Enrico
Hauser, Balázs
author_facet Simon, Florian
Giudici, Ricardo
Scheuerle, Angelika
Gröger, Michael
Asfar, Pierre
Vogt, Josef A
Wachter, Ulrich
Ploner, Franz
Georgieff, Michael
Möller, Peter
Laporte, Régent
Radermacher, Peter
Calzia, Enrico
Hauser, Balázs
author_sort Simon, Florian
collection PubMed
description INTRODUCTION: Infusing arginine vasopressin (AVP) in vasodilatory shock usually decreases cardiac output and thus systemic oxygen transport. It is still a matter of debate whether this vasoconstriction impedes visceral organ blood flow and thereby causes organ dysfunction and injury. Therefore, we tested the hypothesis whether low-dose AVP is safe with respect to liver, kidney, and heart function and organ injury during resuscitated septic shock. METHODS: After intraperitoneal inoculation of autologous feces, 24 anesthetized, mechanically ventilated, and instrumented pigs were randomly assigned to noradrenaline alone (increments of 0.05 μg/kg/min until maximal heart rate of 160 beats/min; n = 12) or AVP (1 to 5 ng/kg/min; supplemented by noradrenaline if the maximal AVP dosage failed to maintain mean blood pressure; n = 12) to treat sepsis-associated hypotension. Parameters of systemic and regional hemodynamics (ultrasound flow probes on the portal vein and hepatic artery), oxygen transport, metabolism (endogenous glucose production and whole body glucose oxidation derived from blood glucose isotope and expiratory (13)CO(2)/(12)CO(2 )enrichment during 1,2,3,4,5,6-(13)C(6)-glucose infusion), visceral organ function (blood transaminase activities, bilirubin and creatinine concentrations, creatinine clearance, fractional Na(+ )excretion), nitric oxide (exhaled NO and blood nitrate + nitrite levels) and cytokine production (interleukin-6 and tumor necrosis factor-α blood levels), and myocardial function (left ventricular dp/dt(max )and dp/dt(min)) and injury (troponin I blood levels) were measured before and 12, 18, and 24 hours after peritonitis induction. Immediate post mortem liver and kidney biopsies were analysed for histomorphology (hematoxylin eosin staining) and apoptosis (TUNEL staining). RESULTS: AVP decreased heart rate and cardiac output without otherwise affecting heart function and significantly decreased troponin I blood levels. AVP increased the rate of direct, aerobic glucose oxidation and reduced hyperlactatemia, which coincided with less severe kidney dysfunction and liver injury, attenuated systemic inflammation, and decreased kidney tubular apoptosis. CONCLUSIONS: During well-resuscitated septic shock low-dose AVP appears to be safe with respect to myocardial function and heart injury and reduces kidney and liver damage. It remains to be elucidated whether this is due to the treatment per se and/or to the decreased exogenous catecholamine requirements.
format Text
id pubmed-2750159
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27501592009-09-25 Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial Simon, Florian Giudici, Ricardo Scheuerle, Angelika Gröger, Michael Asfar, Pierre Vogt, Josef A Wachter, Ulrich Ploner, Franz Georgieff, Michael Möller, Peter Laporte, Régent Radermacher, Peter Calzia, Enrico Hauser, Balázs Crit Care Research INTRODUCTION: Infusing arginine vasopressin (AVP) in vasodilatory shock usually decreases cardiac output and thus systemic oxygen transport. It is still a matter of debate whether this vasoconstriction impedes visceral organ blood flow and thereby causes organ dysfunction and injury. Therefore, we tested the hypothesis whether low-dose AVP is safe with respect to liver, kidney, and heart function and organ injury during resuscitated septic shock. METHODS: After intraperitoneal inoculation of autologous feces, 24 anesthetized, mechanically ventilated, and instrumented pigs were randomly assigned to noradrenaline alone (increments of 0.05 μg/kg/min until maximal heart rate of 160 beats/min; n = 12) or AVP (1 to 5 ng/kg/min; supplemented by noradrenaline if the maximal AVP dosage failed to maintain mean blood pressure; n = 12) to treat sepsis-associated hypotension. Parameters of systemic and regional hemodynamics (ultrasound flow probes on the portal vein and hepatic artery), oxygen transport, metabolism (endogenous glucose production and whole body glucose oxidation derived from blood glucose isotope and expiratory (13)CO(2)/(12)CO(2 )enrichment during 1,2,3,4,5,6-(13)C(6)-glucose infusion), visceral organ function (blood transaminase activities, bilirubin and creatinine concentrations, creatinine clearance, fractional Na(+ )excretion), nitric oxide (exhaled NO and blood nitrate + nitrite levels) and cytokine production (interleukin-6 and tumor necrosis factor-α blood levels), and myocardial function (left ventricular dp/dt(max )and dp/dt(min)) and injury (troponin I blood levels) were measured before and 12, 18, and 24 hours after peritonitis induction. Immediate post mortem liver and kidney biopsies were analysed for histomorphology (hematoxylin eosin staining) and apoptosis (TUNEL staining). RESULTS: AVP decreased heart rate and cardiac output without otherwise affecting heart function and significantly decreased troponin I blood levels. AVP increased the rate of direct, aerobic glucose oxidation and reduced hyperlactatemia, which coincided with less severe kidney dysfunction and liver injury, attenuated systemic inflammation, and decreased kidney tubular apoptosis. CONCLUSIONS: During well-resuscitated septic shock low-dose AVP appears to be safe with respect to myocardial function and heart injury and reduces kidney and liver damage. It remains to be elucidated whether this is due to the treatment per se and/or to the decreased exogenous catecholamine requirements. BioMed Central 2009 2009-07-10 /pmc/articles/PMC2750159/ /pubmed/19591694 http://dx.doi.org/10.1186/cc7959 Text en Copyright ©2009 Simon et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Simon, Florian
Giudici, Ricardo
Scheuerle, Angelika
Gröger, Michael
Asfar, Pierre
Vogt, Josef A
Wachter, Ulrich
Ploner, Franz
Georgieff, Michael
Möller, Peter
Laporte, Régent
Radermacher, Peter
Calzia, Enrico
Hauser, Balázs
Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial
title Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial
title_full Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial
title_fullStr Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial
title_full_unstemmed Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial
title_short Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial
title_sort comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750159/
https://www.ncbi.nlm.nih.gov/pubmed/19591694
http://dx.doi.org/10.1186/cc7959
work_keys_str_mv AT simonflorian comparisonofcardiachepaticandrenaleffectsofargininevasopressinandnoradrenalineduringporcinefecalperitonitisarandomizedcontrolledtrial
AT giudiciricardo comparisonofcardiachepaticandrenaleffectsofargininevasopressinandnoradrenalineduringporcinefecalperitonitisarandomizedcontrolledtrial
AT scheuerleangelika comparisonofcardiachepaticandrenaleffectsofargininevasopressinandnoradrenalineduringporcinefecalperitonitisarandomizedcontrolledtrial
AT grogermichael comparisonofcardiachepaticandrenaleffectsofargininevasopressinandnoradrenalineduringporcinefecalperitonitisarandomizedcontrolledtrial
AT asfarpierre comparisonofcardiachepaticandrenaleffectsofargininevasopressinandnoradrenalineduringporcinefecalperitonitisarandomizedcontrolledtrial
AT vogtjosefa comparisonofcardiachepaticandrenaleffectsofargininevasopressinandnoradrenalineduringporcinefecalperitonitisarandomizedcontrolledtrial
AT wachterulrich comparisonofcardiachepaticandrenaleffectsofargininevasopressinandnoradrenalineduringporcinefecalperitonitisarandomizedcontrolledtrial
AT plonerfranz comparisonofcardiachepaticandrenaleffectsofargininevasopressinandnoradrenalineduringporcinefecalperitonitisarandomizedcontrolledtrial
AT georgieffmichael comparisonofcardiachepaticandrenaleffectsofargininevasopressinandnoradrenalineduringporcinefecalperitonitisarandomizedcontrolledtrial
AT mollerpeter comparisonofcardiachepaticandrenaleffectsofargininevasopressinandnoradrenalineduringporcinefecalperitonitisarandomizedcontrolledtrial
AT laporteregent comparisonofcardiachepaticandrenaleffectsofargininevasopressinandnoradrenalineduringporcinefecalperitonitisarandomizedcontrolledtrial
AT radermacherpeter comparisonofcardiachepaticandrenaleffectsofargininevasopressinandnoradrenalineduringporcinefecalperitonitisarandomizedcontrolledtrial
AT calziaenrico comparisonofcardiachepaticandrenaleffectsofargininevasopressinandnoradrenalineduringporcinefecalperitonitisarandomizedcontrolledtrial
AT hauserbalazs comparisonofcardiachepaticandrenaleffectsofargininevasopressinandnoradrenalineduringporcinefecalperitonitisarandomizedcontrolledtrial